Elevated myo-inositol, choline, and glutamate levels in the associative striatum of antipsychotic-naive patients with first-episode psychosis: A proton magnetic resonance spectroscopy study with implications for glial dysfunction

Schizophrenia Bulletin

Volumn 42, Issue 2, 2016, Pages 415-424

  Plitman, Eric ^a,b   de la Fuente Sandoval, Camilo ^c   Reyes Madrigal, Francisco ^c   Chavez, Sofia ^a   Gómez Cruz, Gladys ^c   León Ortiz, Pablo ^c   Graff Guerrero, Ariel ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

Author keywords

Astrocyte; Glutamatergic; MRS schizophrenia; Neuroinflammation; Positive symptoms

Indexed keywords

CHOLINE; GLUTAMIC ACID; GLUTAMINE; INOSITOL; N ACETYLASPARTIC ACID; NEUROLEPTIC AGENT; ASPARTIC ACID; N-ACETYLASPARTATE;

ADULT; ARTICLE; BRIEF PSYCHOTIC DISORDER; CELL ACTIVATION; CEREBROSPINAL FLUID; CHEMICAL COMPOSITION; CONTROLLED STUDY; CORPUS STRIATUM; GLIA CELL; GLUTAMATERGIC SYNAPSE; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; NEUROTRANSMISSION; NUCLEAR MAGNETIC RESONANCE SCANNER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; ANALOGS AND DERIVATIVES; GLIA; METABOLISM;

ADULT; ASPARTIC ACID; CHOLINE; CORPUS STRIATUM; GLUTAMIC ACID; GLUTAMINE; HUMANS; INOSITOL; NEUROGLIA; PROTON MAGNETIC RESONANCE SPECTROSCOPY; PSYCHOTIC DISORDERS; SCHIZOPHRENIA;

EID: 84964906124     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbv118     Document Type: Article

References (90)

1. Bernstein HG, Steiner J, Guest PC, Dobrowolny H, Bogerts B. Glial cells as key players in schizophrenia pathology: recent insights and concepts of therapy. Schizophr Res. 2015;161:4-18.
2. Goudriaan A, de Leeuw, C, Ripke S, et al. Specific glial functions contribute to schizophrenia susceptibility. Schizophr Bull. 2014;40:925-935.
3. Bustillo JR. Use of proton magnetic resonance spectroscopy in the treatment of psychiatric disorders: A critical update. Dialogues Clin Neurosci. 2013;15:329-337.
4. Chang L, Munsaka SM, Kraft-Terry S, Ernst T. Magnetic resonance spectroscopy to assess neuroinflammation and neuropathic pain. J Neuroimmune Pharmacol. 2013;8:576-593.
5. Malhi GS, Valenzuela M, Wen W, Sachdev P. Magnetic resonance spectroscopy and its applications in psychiatry. Aust N Z J Psychiatry. 2002;36:31-43.
6. Vance AL, Velakoulis D, Maruff P, Wood SJ, Desmond P, Pantelis C. Magnetic resonance spectroscopy and schizophrenia: What have we learnt? Aust N Z J Psychiatry. 2000;34:14-25.
7. Brand A, Richter-Landsberg C, Leibfritz D. Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev Neurosci. 1993;15:289-298.
8. Griffin JL, Bollard M, Nicholson JK, Bhakoo K. Spectral profiles of cultured neuronal and glial cells derived from HRMAS (1)H NMR spectroscopy. NMR Biomed. 2002;15:375-384.
9. Urenjak J, Williams SR, Gadian DG, Noble M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci. 1993;13:981-989.
10. Kraguljac NV, Reid M, White D, et al. Neurometabolites in schizophrenia and bipolar disorder - A systematic review and meta- Analysis. Psychiatry Res. 2012;203:111-125.
11. Kim H, McGrath BM, Silverstone PH. A review of the possible relevance of inositol and the phosphatidylinositol second messenger system (PI-cycle) to psychiatric disorders-focus on magnetic resonance spectroscopy (MRS) studies. Hum Psychopharmacol. 2005;20:309-326.
12. Schwerk A, Alves FD, Pouwels PJ, van Amelsvoort, T. Metabolic alterations associated with schizophrenia: A critical evaluation of proton magnetic resonance spectroscopy studies. J Neurochem. 2014;128:1-87.
13. Kondziella D, Brenner E, Eyjolfsson EM, Sonnewald U. How do glial-neuronal interactions fit into current neurotransmitter hypotheses of schizophrenia? Neurochem Int. 2007;50:291-301.
14. Xia M, Abazyan S, Jouroukhin Y, Pletnikov M. Behavioral sequelae of astrocyte dysfunction: focus on animal models of schizophrenia. Schizophr Res. 2014; doi:10.1016/j.schres.2014.10.044.
15. Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry. 2001;158:1367-1377.
16. Poels EM, Kegeles LS, Kantrowitz JT, et al. Imaging glutamate in schizophrenia: review of findings and implications for drug discovery. Mol Psychiatry. 2014;19:20-29.
17. Stone JM. Imaging the glutamate system in humans: relevance to drug discovery for schizophrenia. Curr Pharm Des. 2009;15:2594-2602.
18. Tsai G, Coyle JT. Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol. 2002;42:165-179.
19. Bustillo JR, Chen H, Jones T, et al. Increased glutamine in patients undergoing long- Term treatment for schizophrenia: A proton magnetic resonance spectroscopy study at 3 T. JAMA Psychiatry. 2014;71:265-272.
20. de la Fuente-Sandoval, C, Leon-Ortiz P, Favila R, et al. Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis. Neuropsychopharmacology. 2011;36:1781-1791.
21. Kraguljac NV, White DM, Reid MA, Lahti AC. Increased hippocampal glutamate and volumetric deficits in unmedicated patients with schizophrenia. JAMA Psychiatry. 2013;70:1294-1302.
22. Kegeles LS, Mao X, Stanford AD, et al. Elevated prefrontal cortex gamma- Aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 2012;69:449-459.
23. Wijtenburg SA, Yang S, Fischer BA, Rowland LM. In vivo assessment of neurotransmitters and modulators with magnetic resonance spectroscopy: Application to schizophrenia. Neurosci Biobehav Rev. 2015;51:276-295.
24. Meyerhoff DJ, MacKay S, Bachman L, et al. Reduced brain N- Acetylaspartate suggests neuronal loss in cognitively impaired human immunodeficiency virus-seropositive individuals: in vivo 1H magnetic resonance spectroscopic imaging. Neurology. 1993;43:509-515.
25. Tsai G, Coyle JT. N- Acetylaspartate in neuropsychiatric disorders. Prog Neurobiol. 1995;46:531-540.
26. Gan JL, Cheng ZX, Duan HF, Yang JM, Zhu XQ, Gao CY. Atypical antipsychotic drug treatment for 6 months restores N- Acetylaspartate in left prefrontal cortex and left thalamus of first-episode patients with early onset schizophrenia: A magnetic resonance spectroscopy study. Psychiatry Res. 2014;223:23-27.
27. Theberge J, Al-Semaan Y, Williamson PC, et al. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am J Psychiatry. 2003;160:2231-2233.
28. Wood SJ, Berger GE, Wellard RM, et al. A 1H-MRS investigation of the medial temporal lobe in antipsychotic-naive and early- Treated first episode psychosis. Schizophr Res. 2008;102:163-170.
29. Howes OD, Montgomery AJ, Asselin MC, et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry. 2009;66:13-20.
30. Kegeles LS, Abi-Dargham A, Frankle WG, et al. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry. 2010;67:231-239.
31. Farde L, Wiesel FA, Halldin C, Sedvall G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry. 1988;45:71-76.
32. Graff-Guerrero A, Willeit M, Ginovart N, et al. Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans. Hum Brain Mapp. 2008;29:400-410.
33. de la Fuente-Sandoval, C, Leon-Ortiz P, Azcarraga M, et al. Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: A longitudinal proton magnetic resonance spectroscopy study. JAMA psychiatry 2013;70:1057-1066.
34. Carpenter WT Jr, Schooler NR, Kane JM. The rationale and ethics of medication-free research in schizophrenia. Arch Gen Psychiatry. 1997;54:401-407.
35. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
36. Provencher SW. Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed. 2001;14:260-264.
37. Jiru F, Skoch A, Klose U, Grodd W, Hajek M. Error images for spectroscopic imaging by LCModel using Cramer-Rao bounds. MAGMA. 2006;19:1-14.
38. Provencher SW. LCModel & LCMgui User's Manual. 2012.
39. Bustillo JR, Rowland LM, Jung R, et al. Proton magnetic resonance spectroscopy during initial treatment with antipsychotic medication in schizophrenia. Neuropsychopharmacology. 2008;33:2456-2466.
40. Auer DP, Wilke M, Grabner A, Heidenreich JO, Bronisch T, Wetter TC. Reduced NAA in the thalamus and altered membrane and glial metabolism in schizophrenic patients detected by 1H-MRS and tissue segmentation. Schizophr Res. 2001;52:87-99.
41. Bustillo JR, Chen H, Gasparovic C, et al. Glutamate as a marker of cognitive function in schizophrenia: A proton spectroscopic imaging study at 4 Tesla. Biol Psychiatry. 2011;69:19-27.
42. Chang L, Friedman J, Ernst T, Zhong K, Tsopelas ND, Davis K. Brain metabolite abnormalities in the white matter of elderly schizophrenic subjects: implication for glial dysfunction. Biol Psychiatry. 2007;62:1396-1404.
43. Lutkenhoff ES, van Erp TG, Thomas MA, et al. Proton MRS in twin pairs discordant for schizophrenia. Mol Psychiatry. 2010;15:308-318.
44. Tayoshi S, Sumitani S, Taniguchi K, et al. Metabolite changes and gender differences in schizophrenia using 3-Tesla proton magnetic resonance spectroscopy (1H-MRS). Schizophr Res. 2009;108:69-77.
45. Bustillo JR, Rowland LM, Lauriello J, et al. High choline concentrations in the caudate nucleus in antipsychotic- naive patients with schizophrenia. Am J Psychiatry. 2002;159:130-133.
46. Fujimoto T, Nakano T, Takano T, et al. Proton magnetic resonance spectroscopy of basal ganglia in chronic schizophrenia. Biol Psychiatry. 1996;40:14-18.
47. Shioiri T, Hamakawa H, Kato T, et al. Proton magnetic resonance spectroscopy of the basal ganglia in patients with schizophrenia: A preliminary report. Schizophr Res. 1996;22:19-26.
48. Maddock R. The problem of spurious correlations between pairs of brain metabolite values measured in the same voxel with magnetic resonance spectroscopy. JAMA Psychiatry. 2014;71:338-339.
49. Chang L, Jiang C, Cunningham E, et al. Effects of APOE e4, age, and HIV on glial metabolites and cognitive deficits. Neurology. 2014;82:2213-2222.
50. Harezlak J, Buchthal S, Taylor M, et al.; HIV Neuroimaging Consortium. Persistence of HIV- Associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment. AIDS. 2011;25:625-633.
51. Inglese M, Li BS, Rusinek H, Babb JS, Grossman RI, Gonen O. Diffusely elevated cerebral choline and creatine in relapsing-remitting multiple sclerosis. Magn Reson Med. 2003;50:190-195.
52. Miller BL, Moats RA, Shonk T, Ernst T, Woolley S, Ross BD. Alzheimer disease: depiction of increased cerebral myo-inositol with proton MR spectroscopy. Radiology. 1993;187:433-437.
53. Chiappelli J, Hong LE, Wijtenburg SA, et al. Alterations in frontal white matter neurochemistry and microstructure in schizophrenia: implications for neuroinflammation. Transl Psychiatry. 2015;5:e548.
54. Fan X, Goff DC, Henderson DC. Inflammation and schizophrenia. Expert Rev Neurother. 2007;7:789-796.
55. Kirkpatrick B, Miller BJ. Inflammation and schizophrenia. Schizophr Bull. 2013;39:1174-1179.
56. Tourjman V, Kouassi E, Koue ME, et al. Antipsychotics' effects on blood levels of cytokines in schizophrenia: A metaanalysis. Schizophr Res. 2013;151:43-47.
57. Nitta M, Kishimoto T, Muller N, et al. Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: A meta- Analytic investigation of randomized controlled trials. Schizophr Bull. 2013;39:1230-1241.
58. Sommer IE, Van Westrhenen, R, Begemann MJ, de Witte, LD, Leucht S, Kahn RS. Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: An update. Schizophr Bull. 2014;40:181-191.
59. Bartha R, Williamson PC, Drost DJ, et al. Measurement of glutamate and glutamine in the medial prefrontal cortex of never- Treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 1997;54:959-965.
60. De la Fuente-Sandoval, C, Leon-Ortiz P, Azcarraga M, Favila R, Stephano S, Graff-Guerrero A. Striatal glutamate and the conversion to psychosis: A prospective 1H-MRS imaging study. Int J Neuropsychopharmacol. 2013;16:471-475.
61. Theberge J, Bartha R, Drost DJ, et al. Glutamate and glutamine measured with 4.0 T proton MRS in never- Treated patients with schizophrenia and healthy volunteers. Am J Psychiatry. 2002;159:1944-1946.
62. Kraguljac NV, Reid MA, White DM, den Hollander, J, Lahti AC. Regional decoupling of N- Acetyl- Aspartate and glutamate in schizophrenia. Neuropsychopharmacology. 2012;37:2635-2642.
63. Poels EM, Kegeles LS, Kantrowitz JT, et al. Glutamatergic abnormalities in schizophrenia: A review of proton MRS findings. Schizophr Res. 2014;152:325-332.
64. Rowland LM, Kontson K, West J, et al. In vivo measurements of glutamate, GABA, and NAAG in schizophrenia. Schizophr Bull. 2013;39:1096-1104.
65. Reid MA, Kraguljac NV, Avsar KB, White DM, den Hollander, JA, Lahti AC. Proton magnetic resonance spectroscopy of the substantia nigra in schizophrenia. Schizophr Res. 2013;147:348-354.
66. Goto N, Yoshimura R, Kakeda S, et al. Six-month treatment with atypical antipsychotic drugs decreased frontal-lobe levels of glutamate plus glutamine in early-stage first-episode schizophrenia. Neuropsychiatr Dis Treat. 2012;8:119-122.
67. Rothermundt M, Ahn JN, Jorgens S. S100B in schizophrenia: An update. Gen Physiol Biophys. 2009;28 Spec No Focus:F76-F81.
68. Linderholm KR, Skogh E, Olsson SK, et al. Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr Bull. 2012;38:426-432.
69. Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ. Kynurenines in the mammalian brain: When physiology meets pathology. Nat Rev Neurosci. 2012;13:465-477.
70. Rowland LM, Bustillo JR, Mullins PG, et al. Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: A 4-T proton MRS study. Am J Psychiatry. 2005;162:394-396.
71. Stone JM, Dietrich C, Edden R, et al. Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ketamine-induced psychopathology. Mol Psychiatry. 2012;17:664-665.
72. Muller N, Schwarz M. Schizophrenia as an inflammationmediated dysbalance of glutamatergic neurotransmission. Neurotox Res. 2006;10:131-148.
73. Muller N. Inflammation and the glutamate system in schizophrenia: implications for therapeutic targets and drug development. Expert Opin Ther Targets. 2008;12:1497-1507.
74. Steiner J, Bogerts B, Sarnyai Z, et al. Bridging the gap between the immune and glutamate hypotheses of schizophrenia and major depression: Potential role of glial NMDA receptor modulators and impaired blood-brain barrier integrity. World J Biol Psychiatry. 2012;13:482-492.
75. Aparicio-Legarza MI, Cutts AJ, Davis B, Reynolds GP. Deficits of [3H]D- Aspartate binding to glutamate uptake sites in striatal and accumbens tissue in patients with schizophrenia. Neurosci Lett. 1997;232:13-16.
76. Lauriat TL, McInnes LA. EAAT2 regulation and splicing: relevance to psychiatric and neurological disorders. Mol Psychiatry. 2007;12:1065-1078.
77. Shan D, Lucas EK, Drummond JB, Haroutunian V, Meador-Woodruff JH, McCullumsmith RE. Abnormal expression of glutamate transporters in temporal lobe areas in elderly patients with schizophrenia. Schizophr Res. 2013;144:1-8.
78. Simpson MD, Slater P, Royston MC, Deakin JF. Regionally selective deficits in uptake sites for glutamate and gammaaminobutyric acid in the basal ganglia in schizophrenia. Psychiatry Res. 1992;42:273-282.
79. Homan P, Vermathen P, Van Swam, C, et al. Magnetic resonance spectroscopy investigations of functionally defined language areas in schizophrenia patients with and without auditory hallucinations. Neuroimage. 2014;94:23-32.
80. Chiappelli J, Rowland LM, Wijtenburg SA, et al. Evaluation of Myo-Inositol as a Potential Biomarker for Depression in Schizophrenia. Neuropsychopharmacology. 2015;40:2157-2164.
81. Hugdahl K, Craven AR, Nygard M, et al. Glutamate as a mediating transmitter for auditory hallucinations in schizophrenia: A (1)H MRS study. Schizophr Res. 2015;161:252-260.
82. Brugger S, Davis JM, Leucht S, Stone JM. Proton magnetic resonance spectroscopy and illness stage in schizophrenia- A systematic review and meta- Analysis. Biol Psychiatry. 2011;69:495-503.
83. Plitman E, Nakajima S, de la Fuente-Sandoval C, et al. Glutamate-mediated excitotoxicity in schizophrenia: A review. Eur Neuropsychopharmacol. 2014;24:1591-1605.
84. Marsman A, van den Heuvel, MP, Klomp DW, Kahn RS, Luijten PR, Hulshoff Pol HE. Glutamate in schizophrenia: A focused review and meta- Analysis of 1H-MRS studies. Schizophr Bull. 2013;39:120-129.
85. Rowland LM, Krause BW, Wijtenburg SA, et al. Medial frontal GABA is lower in older schizophrenia: A MEGAPRESS with macromolecule suppression study. Mol Psychiatry. 2015; doi:10.1038/mp.2015.34.
86. Clementi V, Tonon C, Lodi R, Malucelli E, Barbiroli B, Iotti S. Assessment of glutamate and glutamine contribution to in vivo N- Acetylaspartate quantification in human brain by (1)H-magnetic resonance spectroscopy. Magn Reson Med. 2005;54:1333-1339.
87. de la Fuente-Sandoval, C, Favila R, Alvarado P, et al. Glutamate increase in the associative striatum in schizophrenia: A longitudinal magnetic resonance spectroscopy preliminary study. Gaceta medica de Mexico 2009;145:109-113.
88. Kraguljac NV, Cutter GR, Morgan C, Lahti AC. In reply. JAMA Psychiatry. 2014;71:339-340.
89. Lindenmayer JP. Treatment refractory schizophrenia. Psychiatr Q. 2000;71:373-384.
90. Suzuki T, Remington G, Mulsant BH, et al. Treatment resistant schizophrenia and response to antipsychotics: A review. Schizophr Res. 2011;133:54-62.